Literature DB >> 3366234

Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction?

D S Postma1, I Peters, E J Steenhuis, H J Sluiter.   

Abstract

In a former study in patients with severe chronic airflow obstruction (CAO), (forced expiratory volume in one second (FEV1) ranging from 350-910 ml), we concluded that daily oral corticosteroids might slow down the progression of disease. The results of the present long-term (14-20 yr) study on 139 non-allergic patients with less severe CAO (FEV1 greater than or equal to 1200 ml, FEV1 as a percentage of vital capacity (FEV1%VC) 40-55%) confirm and extend our former observations. Four patterns of the course of FEV1 and inspiratory vital capacity (VC) in time were recognized: 1) linear decrease; 2) no change; 3) initial increase, followed by decrease; 4) initial decrease, followed by increase. Groups 1 and 3 had a higher functional residual capacity as a percentage of total lung capacity (FRC%TLC) as compared to group 2 and 4; the work of breathing was lower in group 2 than in the other three groups. Otherwise the initial 82 parameters, including the degree of reversibility of airflow obstruction and smoking habits were comparable in the four groups. The four patterns of FEV1 showed a strong association with the long-term use of prednisolone. When oral prednisolone was instituted or increased to a dose of at least 10 mg/day continuously, FEV1 either remained constant, decreased more slowly or even increased over many years of follow-up. When the oral dose was diminished to below 10 mg/day, FEV1 decreased.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3366234

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease.

Authors:  B Auffarth; D S Postma; J G de Monchy; T W van der Mark; M Boorsma; G H Koëter
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

2.  Pulmonary function after exposure to the World Trade Center collapse in the New York City Fire Department.

Authors:  Gisela I Banauch; Charles Hall; Michael Weiden; Hillel W Cohen; Thomas K Aldrich; Vasillios Christodoulou; Nicole Arcentales; Kerry J Kelly; David J Prezant
Journal:  Am J Respir Crit Care Med       Date:  2006-04-27       Impact factor: 21.405

3.  BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.

Authors: 
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

Review 4.  Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Marcel Bonay; Catherine Bancal; Bruno Crestani
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 6.  Pulmonary rehabilitation in chronic respiratory insufficiency. 1. Pulmonary rehabilitation in perspective: historical roots, present status, and future projections.

Authors:  T L Petty
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

7.  Inhaled corticosteroids in COPD: awaiting controlled trials.

Authors:  J A Wedzicha
Journal:  Thorax       Date:  1993-04       Impact factor: 9.139

Review 8.  Chronic obstructive pulmonary disease and asthma. General and medical management with special attention to exacerbations.

Authors:  J P Kaajan
Journal:  Pharm Weekbl Sci       Date:  1989-08-25

Review 9.  Treatment of chronic obstructive pulmonary disease in older patients: a practical guide.

Authors:  Abebaw M Yohannes; Christopher C Hardy
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.

Authors:  G T Verhoeven; J P J J Hegmans; P G H Mulder; J M Bogaard; H C Hoogsteden; J-B Prins
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.